Answers are grounded in this paper and cite their sources.
Evaluation reveals that dexmedetomidine enhances anesthetic safety and recovery in C57BL/6 mice, implying a viable ketamine-free option.
Background Ketamine is a widely used anesthetic in animal research, but its use is strictly regulated in several countries, including Japan and China. As an alternative, the medetomidine‐midazolam‐butorphanol (MMB) combination is commonly used in Japan. However, medetomidine is a racemic mixture containing the inactive R‐enantiomer, which may reduce anesthetic predictability and safety. Objective The aim of the study was to evaluate the efficacy and safety of a modified anesthetic combination (dMMB), in which dexmedetomidine replaces medetomidine, across three commonly used mouse strains (ICR, C57BL/6, BALB/c). Methods Male and female mice were administered either MMB or dMMB subcutaneously. Anesthetic depth, recovery profiles, heart rate, SpO 2 , body temperature, ocular opacity, and blood glucose levels were assessed. Atipamezole was used to reverse anesthesia, and thermoregulatory recovery was monitored postinjection. Results dMMB produced similar anesthetic depth to MMB, with faster and more consistent recovery, particularly in males. Body temperature recovery was significantly enhanced in dMMB‐treated B6 males. No significant differences in side effects (ocular opacity or blood glucose levels) were observed between protocols, though strain‐specific glucose elevations were noted in dMMB‐treated males. Conclusion dMMB is a safe, effective, and ketamine‐free injectable anesthetic protocol, offering advantages in recovery and thermoregulation. It may be a valuable alternative in research settings where ketamine is restricted and medetomidine may become unavailable.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: